Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop aims to lower glaucoma pressure

NCT ID NCT07168902

Disease control Sponsor: Bausch & Lomb Incorporated Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This Phase 2 trial tests an experimental eye drop called BL1107 against a standard treatment (timolol) in 252 adults with glaucoma or high eye pressure. Participants use the drops twice daily for 28 days. The study measures changes in vision and eye pressure to see if BL1107 is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BL1107 (experimental eye drop)
What this could lead to
If successful, BL1107 could offer a new option to help control eye pressure and protect vision in people with glaucoma.
What could go wrong
This is an early Phase 2 trial with only 252 participants over 28 days. The new eye drop may not work better than existing treatments, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

252 people

The number who actually took part.

Started

Oct 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Ocular hypertension or primary open-angle glaucoma in each eye Exclusion criteria: * History of orthostatic hypotension * Any active ocular disease * Anticipated wearing of contact lenses during study * Contraindication to pupil dilation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

Contacts and locations

Locations

  • Andover Eye Associates

    Andover, Massachusetts, 01810, United States

  • California Eye Specialist Medical Group, LLC

    Pasadena, California, 91107, United States

  • Central Florida Eye Associates

    Lakeland, Florida, 33805, United States

  • Clayton Eye Clinical Research, LLC

    Morrow, Georgia, 30260, United States

  • Coastal Research Associates, LLC

    Roswell, Georgia, 30076, United States

  • Eye Associates of Fort Myers

    Fort Myers, Florida, 33901, United States

  • Eye Research Foundation

    Newport Beach, California, 92663, United States

  • Global Research Management, Inc.

    Glendale, California, 91204, United States

  • Heart of America Eye Care

    Shawnee Mission, Kansas, 66204, United States

  • Houston Eye Associates

    Houston, Texas, 77025, United States

  • Lee Shettle Eye and Hearing

    Largo, Florida, 33773, United States

  • Levenson Eye Associates

    Jacksonville, Florida, 32204, United States

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania, 16066, United States

  • Total Eye Care, P.A.

    Memphis, Tennessee, 38119, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.